Dr. Raoul Tibes serves as the Director of the Hematological Malignancy Program at the Translational Genomics Research Institute (TGen). He is a physician-scientist specializing in myeloid malignancies like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He earned his M. D. and Ph. D. in Germany and focuses on translating genomic discoveries into early-phase clinical trials.
Raoul Tibes
Director, Hematological Malignancy Program at Translational Genomics Research Institute
Scottsdale, Arizona, United States
Overview
Topics They Care About
Myeloid Malignancies
His primary clinical and research focus is on developing novel therapies for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Translational Research
His work centers on moving preclinical results and genomic discoveries from the laboratory into innovative, biomarker-driven clinical trials for patients.
Targeted Cancer Therapy
He has a deep expertise in developing and testing novel targeted drugs, including smoothened (SMO)/Hedgehog pathway inhibitors and WEE1 kinase inhibitors.
Media Appearances
Raoul has no verified media appearances
Work History
Director, Hematological Malignancy Program at Translational Genomics Research Institute
Education
Raoul has no verified education history
More Information
Social Presence :
Prographics :
Exp : N/A
Location : Scottsdale, Arizona, United States
Job Level : Mid-senior
Designation : Director, Hematological Malignancy Program at Translational Genomics Research Institute
